Pharmachronicles

Top Menu

  • Home
  • Our Blog
  • Contact Us

Main Menu

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
Sign in / Join

Login

Welcome! Login in to your account
Lost your password?

Lost Password

Back to login
  • Home
  • Our Blog
  • Contact Us

Pharmachronicles

Header Banner

Pharmachronicles

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
  • UGC-Cancelled-List of journals

  • NAAC stops accepting applications for accreditation from pharmacy colleges

  • Pursuing MPhil/PhD while working as a teacher will effect experience: UGC

  • Public notice by government of india ministry of health and family welfare

BLOGS
Home›BLOGS›New malaria drug AQ-13 found effective in human trial

New malaria drug AQ-13 found effective in human trial

By admin
September 14, 2017
539
0
Share:

With the parasite responsible for most malaria cases, Plasmodium falciparum, developing resistance to widely-used treatments, researchers have developed a new drug to fight the mosquito-born disease. Results of a clinical trial published in the journal Lancet Infectious Diseases have shown the drug to be effective against non-severe cases of malaria.

The drug, called AQ-13, was able to clear the parasite responsible for the disease within a week, matching the effectiveness of the most widely-used treatment regimen, the study said. “The clinical trial results are extraordinarily encouraging,” said the study’s senior author Donald Krogstad, Professor at Tulane University in New Orleans, Louisiana.

“Compared to the current first-line recommendation for treatment of malaria, the new drug comes out very well,” Krogstad said.

Mosquitoes infected by a parasite spread malaria, causing more than 200 million illnesses across the globe and more than 400,000 deaths annually.

For decades, chloroquine was used to treat malaria, until Plasmodium falciparum developed resistance to it. Now, a drug combination — artemether and lumefantrine — is the primary treatment for malaria, although resistance is also developing to the drug combination in some countries. The researchers recruited 66 adult men in Mali with uncomplicated malaria, which is defined as malaria that is not life-threatening. Half were treated with AQ-13 and the other half received artemether and lumefantrine. Both drug groups had similar cure rates, the study said. The researchers hope to expand testing of the drug to more participants, including women and children, before it can be widely recommended as a new treatment. The same biotechnology that helped the team develop the new drug has also identified similar drugs that also hold promise against drug-resistant parasites, Krogstad said.

“The potential long-term implications are bigger than one drug,” he said. “The conceptual step here is that if you understand the resistance well enough, you may be actually be able to develop others as well. We synthesized over 200 analogues and, of those, 66 worked against the resistant parasites,” Krogstad said.

TagsAQ-13malaria drug
Previous Article

Osmania Univ Ph.D. Eligibility Test-2016 Results

Next Article

Useful websites and online educational support.

0
Shares
  • 0
  • +
  • 0
  • 0
  • 0
  • 0

admin

Related articles More from author

  • FDA Alerts

    FDA approves a new drug to treat malaria which could help millions.

    July 24, 2018
    By Sriram Nagarajan
  • Phama news

    CONGESTIVE CARDIAC FAILURE

    December 26, 2019
    By Sriram Nagarajan
  • Phama news

    OSTEOPOROSIS

    January 13, 2020
    By Sriram Nagarajan
  • BLOGS

    NEW TOOL FOR THE IDENTIFICATION OF MALARIA

    October 24, 2017
    By admin
  • BLOGS

    CSIR EXAM NOTIFICATION

    September 27, 2017
    By admin
  • BLOGS

    FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    July 16, 2015
    By admin

Leave a reply Cancel reply

You may interested

  • BLOGS

    Besponsa (inotuzumab ozogamicin) a new FDA approved drug

  • BLOGS

    Industry wary over government’s new pharma policy

  • Uncategorized

    Top MBA specializations to choose

  • LATEST REVIEWS

  • TOP REVIEWS

  • Pharmacists are not eligible for certificate program of community health

    0
  • A New Class of Antimicrobials Has Just Been Found in Human Breast Milk Fresh super ...

    0

Timeline

  • October 20, 2020

    List of UGC Approved journals 2020

  • August 8, 2020

    LIST OF SCOPUS INDEXED JOURNALS JUNE 2020

  • June 8, 2020

    Brain Tumor Day -8th June – Endoscopic surgery: An innovative approach to treat brain tumour

  • June 4, 2020

    UGC-Cancelled-List of journals

  • June 1, 2020

    Saroj Group Of Hospitals restarts its complete operations – see major footfall in OPD consultation

Latest Comments

  • ActionScheduler
    on
    March 9, 2020
    action complete

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action created

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action started

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action complete

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action created

    wc_admin_unsnooze_admin_notes

Find us on Facebook

Follow Us on Instagram

logo

Dui viverra Faucibus aliquet quis phasellus accumsan. Donec et facilisis sociosqu sed tortor elit eu aliquid turpis ridiculus.

Fly, shall, have greater fifth spirit midst under from stars thing is, had creepeth multiply kind. Man may they’re meat years have third bring replenish air two light deep fill.

About us

  • Dr.N.Sriram, Founder CEO, Pharmachronicles, HITS college of Pharmacy, Ghatkesar, Hyderabad, India
  • 9704361947
  • pharmachronicles@gmail.com
  • Recent

  • Popular

  • Comments

  • List of UGC Approved journals 2020

    By admin
    October 20, 2020
  • LIST OF SCOPUS INDEXED JOURNALS JUNE 2020

    By admin
    August 8, 2020
  • Brain Tumor Day -8th June – Endoscopic surgery: An innovative approach to treat brain tumour

    By Sriram Nagarajan
    June 8, 2020
  • UGC-Cancelled-List of journals

    By admin
    June 4, 2020
  • FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    By admin
    July 16, 2015
  • Record Numbers of FDA‑Approved Drugs: Recent Trends

    By admin
    July 16, 2015
  • There make for Sixth that multiply blessed two divide creeping

    By admin
    July 16, 2015
  • FDA approved new drugs 2017

    By admin
    July 16, 2015
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action complete
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action created
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action started
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action complete

Photostream

    Follow us

    • Contact
    • STUDENTS ZONE
    • About Us
    © Copyright Pharmachronicles. All rights reserved.